Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Trial Profile

A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Discontinued
Phase of Trial: Phase III

Latest Information Update: 16 Jul 2019

At a glance

  • Drugs Pacritinib (Primary)
  • Indications Myelofibrosis
  • Focus Registrational; Therapeutic Use
  • Acronyms PERSIST-2
  • Sponsors Cell Therapeutics; CTI BioPharma
  • Most Recent Events

    • 04 Dec 2018 Results of pooled analysis of all available TSS data from PERSIST 1 and PERSIST 2 was undertaken to further evaluate TSS response presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 09 Mar 2018 According to a CTI BioPharma media release, results from this trial have been published online in JAMA Oncology.
    • 09 Mar 2018 Results published in the According to a CTI BioPharma media release,Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top